BioMarin Pharmaceutical

Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand
Biotech

BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect

BioMarin has followed through on its shift to external innovation, inking a deal to add a phase 3 enzyme replacement therapy to its pipeline.
Nick Paul Taylor May 16, 2025 8:46am
Graphic image of a pen signing a signature while two strangelooking business people cheer

Spruce inks deal for BioMarin asset, plans 2026 approval filing

Apr 15, 2025 10:29am
Motion blurs of people hurrying around an office

BioMarin's R&D head hopes pipeline of good ideas won't 'dry out'

Feb 21, 2025 7:00am
campfire in forest wilderness

BioMarin goes CAMPing, striking RNA deal with biotech

Oct 1, 2024 9:55am
Graphic image of an arrow nailing the bullseye of a target

Ascendis' dwarfism drug hits in phase 3, threatens BioMarin

Sep 17, 2024 9:36am
Paragliding over the cliffs Fort Funston San Francisco

BioMarin builds exec team with biotech vets—Chutes & Ladders

Aug 23, 2024 8:30am